Mesalazine release from a pH dependent formulation: Effects of omeprazole and lactulose co-administration

British Journal of Clinical Pharmacology

Volumn 46, Issue 2, 1998, Pages 173-175

  Hussain, F N ^a   Ajjan, R A ^a   Moustafa, M ^a   Weir, N W ^a   Riley, S A ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Delayed release mesalazine; Lactulose; Omeprazole; pH dependent drug delivery; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; DRUG METABOLITE; LACTULOSE; MESALAZINE; OMEPRAZOLE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FECES LEVEL; DRUG RELEASE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; STEADY STATE; SUSTAINED RELEASE PREPARATION;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; GASTROINTESTINAL AGENTS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; LACTULOSE; MESALAMINE; MIDDLE AGED; OMEPRAZOLE;

EID: 0031877236     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00762.x     Document Type: Article

References (14)

1. Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196-200.
2. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-1389.
3. Riley SA, Tavares IA, Bennett A, Mani V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol 1988; 26: 173-177.
4. Dew MJ, Hughes PJ, Lee MJ, Evans B, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405-408.
5. Staerk Laursen L, Stockholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-1276.
6. Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-ammosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-1630.
7. Gustavsson S, Adami H-O, Loof L, Nyberg A, Nyren O. Rapid healing of duodenal ulcers with omeprazole. Lancet 1983; ii: 124-125.
8. Zeitoun P, Desjars de Keranroue N, Isal JP. Omeprazole versus ranitidine in erosive oesophagitis. Lancet 1987; ii: 621-622.
9. Bendtsen F, Ovesen L, Rosenkilde-Gram B, Rune SJ. Effect of omeprazole on intragastric and duodenal bulb acidity in duodenal ulcer patients. Aliment Pharmacol Ther 1989; 3: 151-158.
10. Rasmussen L, Oster-Jorgensen E, Qvist N, Kraglund K, Hovendal C, Pendersen SA. Short report: a double-blind placebo-controlled trial of omeprazole on characteristics of gastric emptying in healthy subjects. Aliment Pharmacol Ther 1991; 5: 85-89.
11. Rijk MCM, Van Hogezand RA, Van Schaik A, Van Tongeren JHM. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol 1989; 24: 1179-1185.
12. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut 1974; 15: 999-1004.
13. Stockley IH. Drug interactions: A source of adverse interactions, their mechanisms, clinical importance and management. Third Edition, Oxford: Blackwell Scientific Publications, 1994: 174-175.
14. Cummmings JH, Wiggins HS. Transit through the gut measured by analysis of a single stool. Gut 1976; 17: 219-223.